Pulse Biosciences targets early October enrollment completion for 164-patient NANOPULSE-AF study (NASDAQ:PLSE)
· seekingalpha.com
Pulse Biosciences (PLSE) Q2 2026 earnings call: fast NANOPULSE-AF enrollment to early Oct, CE Mark timeline, revenue & cash runway.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...